Novel molecular targets in the treatment of systemic lupus erythematosus
- 31 January 2008
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 7 (3), 256-261
- https://doi.org/10.1016/j.autrev.2007.11.020
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Oncogenic inflammation and autoimmune diseaseAutoimmunity Reviews, 2006
- Decreased expression levels of CD22 and L-selectin on peripheral blood B lymphocytes from patients with bullous pemphigoidJournal of Autoimmunity, 2006
- Immunohistopathology of Sjögren's syndromeAutoimmunity Reviews, 2006
- Neuromyelitis optica — Devic's syndrome, updateAutoimmunity Reviews, 2006
- FOXP3 polymorphisms in type 1 diabetes and coeliac diseaseJournal of Autoimmunity, 2006
- Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosusJournal of Autoimmunity, 2006
- N-3 fatty acids modulate Th1 and Th2 dichotomy in diabetic pregnancy and macrosomiaJournal of Autoimmunity, 2006
- Transcriptional repression of interleukin-2 in human systemic lupus erythematosusAutoimmunity Reviews, 2006
- Reconstitution of deficient T cell receptor ζ chain restores T cell signaling and augments T cell receptor/CD3–induced interleukin‐2 production in patients with systemic lupus erythematosusArthritis & Rheumatism, 2003
- Prevalence of T cell receptor ζchain deficiency in systemic lupus erythematosusLupus, 2003